Tokyo, Japan

Seiichiro Kawashima




Average Co-Inventor Count = 5.9

ph-index = 6

Forward Citations = 201(Granted Patents)


Location History:

  • Ohizumi-machi, JP (2003)
  • Tokyo, JP (2000 - 2010)
  • Saitama-ken, JP (2010)

Company Filing History:


Years Active: 2000-2010

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Seiichiro Kawashima: Innovator in Heterocyclic Compounds

Introduction

Seiichiro Kawashima is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of chemistry, particularly in the development of heterocyclic compounds. With a total of 11 patents to his name, Kawashima's work has had a notable impact on the pharmaceutical industry.

Latest Patents

Kawashima's latest patents include innovative compounds that serve as anti-malignant tumor agents. One of his notable inventions is a heterocyclic compound represented by a specific formula, which includes various substituents that enhance its effectiveness. Another significant patent focuses on cerebral function improvers, showcasing his versatility in addressing complex health issues through chemical innovation.

Career Highlights

Throughout his career, Kawashima has been associated with Zenyaku Kogyo Kabushiki Kaisha, where he has played a crucial role in advancing research and development. His expertise in heterocyclic compounds has positioned him as a key figure in the company, contributing to its reputation for innovation in the pharmaceutical sector.

Collaborations

Kawashima has collaborated with esteemed colleagues such as Toshiyuki Matsuno and Shinichi Yaguchi. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the quality of their research.

Conclusion

Seiichiro Kawashima's contributions to the field of heterocyclic compounds exemplify his dedication to innovation and research. His patents not only reflect his expertise but also his commitment to improving health outcomes through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…